EU Pharmacovigilance legislation implementation likely to be staggered
This article was originally published in Scrip
As the European Medicines Agency struggles to finance implementing the far reaching pharmacovigilance legislation, it looks as if the new requirements will be introduced in phases beyond the original July 2012 implementation deadline, confirmed Peter Arlett, head of pharmacovigilance and risk management at the European Medicines Agency.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.